Aug 08, 2023 / 08:30PM GMT
Operator
Welcome to Acorda Therapeutics' Second Quarter 2023 Financial Business Update. (Operator Instructions) Please be advised that this call is being recorded at the company request. I will now introduce your host for today's call, Tierney Saccavino with Acorda. Tierney, please go ahead.
Tierney Saccavino - Acorda Therapeutics, Inc. - EVP of Corporate Communications
Thank you, Lauren, and good afternoon, everyone. Before we begin, let me remind you that our presentation will contain forward-looking statements. Detailed disclosures can be found in our SEC filings, which are public, and we encourage you to refer to those filings. Today, during the Q&A, we'll take questions from some of the investors that have been written in.
And I'll now pass the call over to our CEO, Ron Cohen. Ron?
Ron Cohen - Acorda Therapeutics, Inc. - Founder, CEO, President & Director
Thanks, Tierney, and good afternoon, everyone. So INBRIJA U.S. net revenue for the second quarter of 2023 was $8.3 million. That's a 12% increase over
Q2 2023 Acorda Therapeutics Inc Earnings Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers